VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan. 4, 2006--MIV Therapeutics, Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems, has reported significant progress in a report outlining the achievement of numerous key strategic, corporate and technological objectives for 2005.

ADVERTISEMENT

"The past year has been a time of great progress on numerous fronts for all of us at MIVT, and the interest we've generated in the marketplace has been reflected, we believe, in the appreciation in our stock price and shareholder value over the past 12 months," said Alan Lindsay, President and CEO of MIVT. "Our technology and development programs have been validated repeatedly, most importantly by the exceptionally promising results of our research studies, as well as by scientific leaders and key observers in the biomedical community, who have singled out our solutions for special recognition. We have also made substantial progress in building our intellectual property portfolio through acquisition and other key strategic accomplishments."

MIVT's achievements for 2005 include the following milestones.

Research & Development Milestones

Arc Rajtar, MIVT Chief Technology Officer, said: "Our R&D program successfully achieved a number of critical milestones in 2005. We completed all our objectives on schedule and on budget. Additionally, development of our polymer-free drug eluting system was accelerated 6 months ahead of schedule and the preliminary evaluation of this unique technology has already delivered very exciting preliminary results. In line with our earlier statements we are also actively working on broadening the field of use of our coatings beyond cardiovascular applications. We are looking forward to continued progress in 2006, and expect to position our technology firmly on the doorstep of successful commercialization."

"The exceptional results from the porcine animal trials indicated that MIVT's Hydroxyapatite-based coatings are excellent candidates for advanced drug-eluting stent coatings and their outstanding biocompatibility and safety, bringing a promise of unique therapeutic capabilities," said Mr. Rajtar. "Our leadership in this field has also been recognized through invitation to present our technology at a number of leading scientific conferences, and by respected independent industry observers, such as Frost & Sullivan, which named MIVT winner of its prestigious 2005 Award for Technology Innovation in the Field of Advanced Medical Coatings."

• MIVT completes successful preliminary studies performed on different formulations of biocompatible Hydroxyapatite (HAp) ultra-thin coating specifically designed for cardiovascular stents. Independent histopathology studies also confirmed excellent biocompatibility and safety of the proprietary HAp coating for vascular applications. (March 2005)
• MIVT files two new patent applications for inventions developed by the Company's R&D Team, which are expected to enable the development and manufacture of a novel class of advanced composite drug-eluting coatings capable of delivering multiple drugs from a single implantable medical device. (April 2005.)
• MIVT reports on positive results from several animal studies of the proprietary ultra-thin HAp coating. Consistent and problem-free performance of stents with MIVT's proprietary coatings confirms exceptional safety and biocompatibility of HAp passive coating technologies. (April 2005)
• Cardiovascular stents coated with MIVT's proprietary composite drug-eluting coating demonstrated at the one-month follow up stage uncompromised and exceptional biocompatibility and safety. The low amount of neointima ranks with the performance of the best contemporary stents described in literature utilizing a similar experimental setting. (April 2005.)
• MIVT commences trials of its Aortic Embolic Protection Device (AEPD), a unique proprietary filtration device developed by SagaX Medical Technologies, a company that has been acquired by MIVT. AEPD is designed to divert particles that might otherwise reach the brain and cause strokes. (May 2005)
• A three-month follow-up phase of a porcine implantation study of HAp-coated cardiovascular stents demonstrates excellent safety and feasibility of MIVT's HAp-based coating technologies. (June 2005)
• MIV Therapeutics' Intellectual Property Portfolio Expands to 43 Patents, Patent Applications and Licenses on Novel Technologies; Aggressive IP Protection of Coating Technologies Positions Company for Entry into $100 Billion Drug-Delivery Market (September 2005)
• MIV Therapeutics Files both US and International Patents for Breakthrough Smart III Nanoparticle Drug Delivery System. Cutting-Edge Nanotechnology Particulate Composite System Could Revolutionize Drug Delivery Methods to Treat Major Diseases. (October 2005)
• MIVT's Proprietary Stent Coating Technology Completes six-month GLP-compliant porcine study with excellent results. (November 2005)
• MIV Therapeutics Reports Highly Favorable Results in Preclinical Study of Innovative Stroke Prevention Device. Unique Implantable Anti-Stroke Device Progress on Track for Approval and Potential Commercialization (December 2005)

Business and Financing Achievements

"Achievements such as our agreements to acquire Sahajanand and SagaX are designed to significantly broaden MIVT's portfolio of technology and expertise, and are expected to provide a major boost to its marketing, commercialization and revenue objectives," said Mr. Lindsay.

• MIVT executes a Letter of Intent to acquire Sahajanand Medical Technologies (SMT), one of the world's largest manufacturers of advanced coronary stents. Based in Surat, India, SMT is a leader in the use of high-precision laser technology, and a leading manufacturer of state-of-the-art drug-eluting and non-drug-eluting stents. Established in 1997, SMT is the largest privately-held producer of coronary drug-eluting stents outside of North America, with its stent products sold in more than 33 countries and used in more than 30,000 implants. The Company expects to cross the benchmark of 50,000 implanted stents this year. (March 2005)
• MIVT acquires SagaX Medical Technologies, a privately held company developing a unique Aortic Embolic Protection Device (AEPD). The AEPD is expected to decrease likelihood of strokes and other frequent, serious complications that can result from cardiac procedures, as well as from naturally occurring Cardioembolic Strokes. The market for AEPD is estimated to exceed $1.5 billion by 2009. (March 2005)
• MIVT receives governmental Natural Sciences and Engineering Research Council of Canada (NSERC) grant for research program entitled, "Development of Novel Drug-Eluting Composite Coatings for Cardiovascular Stents." The research is being conducted by MIVT subsidiary MIVI Technologies, Inc. in cooperation with scientists from the University of British Columbia. (March 2005)
• MIVT exercises the option provided in its Collaborative Research Agreement with the University British Columbia to license four additional technologies for advanced biocompatible and drug-eluting coatings for cardiovascular stents and other medical devices to further the Company's research and development program. (June 2005)
• MIV Therapeutics Closes 4.14 Million Equity Financing (August 2005)

Industry Recognitions and Scientific Presentations

• Dr. Dov Shimon, Chief Medical Officer and Director of MIV Therapeutics, Inc. presents MIVT's business and growth strategy based on the Company's unique HAp-based multi-layer/multi-drug delivery systems for vascular stents at the Third Annual Biotechnology Conference in New York, N.Y. (April 2005)
• Dr. Tom Troczynski, PhD, Vice President of Coatings of MIV Therapeutics, Inc., and a Professor of Ceramics at UBCeram in the Materials Engineering Dept. of the University of British Columbia, delivers a public presentation entitled, "Progress in Development of Composite Calcium Phosphate Coatings for Stents," and other MIVT Advanced Coating Technologies at the 4th European Symposium of Vascular Biomaterials in Strasbourg, France. (May 2005)
• MIV Therapeutics makes debut at the Paris Course on Revascularization (PCR2005) in Paris, France, sharing an exposition booth with potential future partner, Sahajanand Medical Technologies, Pvt. Ltd. (May 2005)
• MIVT is featured in a recent edition of respected European medical industry publication, Cardiovascular News. (June 2005)
• MIV Therapeutics Special Advisor on Scientific and International Affairs, Dr. Arun Chockalingam, Named Secretary General of World Hypertension League (July 2005)
• MIV Therapeutics Reaffirms Leadership in Advanced Biocompatible Stent Coating Technology at 6th Pacific Rim Conference on Ceramics and Glass Technology (September 2005)
• MIV Therapeutics' Proprietary Stent Coating Studies Presented at World-class Transcatheter Cardiovascular Therapeutics (TCT2005) Conference in Washington DC by Independent Researchers. (October 2005)
• MIV Therapeutics Officially Named Winner of Prestigious Award for Innovation in Advanced Biomedical Technology. Frost & Sullivan Report Praises MIVT Proprietary Biocompatible Coating Technology for Stents and Other Biomedical Devices (October 2005)
• MIV Therapeutics Premiers Research into Superior Polymer-free Drug Delivery Systems at the 2005 Materials & Processes for Medical Devices Conference in Boston, MA. Company Briefs Industry and Science Professionals on Progress to Develop Safer, Better Drug-Eluting Stent Coating. (November 2005)

Strengthened Management

• Dr. Dean-Mo Liu, Ph.D., nominated as the Chief Scientist, Drug Delivery Technologies of MIV Therapeutics, Inc. Dr. Liu has achieved industry-wide distinction through his scientific research to develop novel bioceramics for biomedical applications. He has specialized in the creation of advanced synthesis methods for porous ceramics, and has pioneered new organic formulations for a range of biomedical and other scientific applications. Dr. Liu is responsible for product development initiatives centering on biocompatible coating for drug-eluting cardiovascular stents and other implanted medical devices. Dr. Liu's extensive list of achievements include authoring or direct contribution to 113 scientific publications, 26 conference papers, 8 patents and 3 scientific books. Dr. Liu earned a Ph.D. at the Metals and Materials Engineering Department of the University of British Columbia. He received a Masters of Science degree in Materials Science and Engineering from Virginia Polytechnic Institute and State University, in Blacksburg, VA, and earned both a Bachelors and Masters of Science degrees in Chemical Engineering from Chung Yuan Christian University in Taiwan. (March 2005)
• Dhirajlal Kotadia, founder and CEO of India-based advanced stent manufacturer, Sahajanand Medical Technologies, is appointed to the position of Co-Chairman and Managing Director of International Operations for MIVT. Mr. Kotadia pioneered the use of advanced laser cutting technology that transformed the jewelry diamond-cutting industry, founded Sahajanand Medical Technologies in 1998 and has since built the company into the third-largest maker of drug-eluting stents in the world. (May 2005)
• Dr. Arun Chockalingam, the Company's Special Advisor on Scientific and International Affairs, named to a key leadership role at the World Hypertension League, a federation of the international medical community's most important health care organizations. Effective December 1, 2005, Dr. Chockalingam took the position of Secretary General of the World Hypertension League (WHL), a non-governmental organization with official relationships to leading global health care groups such as the World Health Organization, the International Society of Hypertension and others. The appointment reflected recognition of Dr. Chockalingam's status as a world authority on cardiovascular health and international medical policy. Dr. Chockalingam continues serving as Special Advisor on Scientific and International Affairs at MIVT. (July 2005).
• Arc Rajtar promoted to the position of Chief Technology Officer. An adjunct professor at the University of British Columbia's Faculty of Metals and Materials Engineering he is also a Director of MIVI Technologies Inc., a wholly-owned manufacturing and research and development arm of MIVT. He coordinates research and validation programs, and provides support to business development initiatives towards commercialization of MIVT's proprietary coating and drug delivery technologies. (September 2005)

About MIV Therapeutics

MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and exceptional biocompatibility pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug-eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug-eluting coatings currently in the stent market. The Company's drug-eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

MIV Therapeutics, Inc.
Investor Relations, 604-301-9545 x14
Toll-free: 800-221-5108
Fax: 604-301-9546
E-mail: investor@mivtherapeutics.com
Web: http://www.mivtherapeutics.com/
or, for Product Inquiries and Business Opportunities:
Arc Rajtar, 604-301-9545 Ext. 22
arajtar@mivi.ca
or
Trilogy Capital Partners
Paul Karon, Toll-free: 800-342-1467
paul@trilogy-capital.com